Researchers sought to determine whether CAR-T therapy could improve HR-QoL scores for patients with relapsed or refractory multiple myeloma.

Multiple Myeloma (MM), a chronic and currently incurable hematologic malignancy, remains one of the most dynamic and competitive therapeutic landscapes in oncology. Originating from abnormal plasma ...

Early intervention in high-risk smoldering myeloma with lenalidomide delays progression by up to 7 years and achieves ...

The debate between CAR T-cell therapy and bispecific antibodies is not a rivalry but a question of sequencing, ...

For people with newly diagnosed multiple myeloma (NDMM), who are unsuitable for a procedure where damaged blood cells are replaced with healthy ones (stem-cell transplant), treatment is usually a ...

Lynozyfic’s global sales are projected to reach $707 million by 2031.

Copyright: © 2022 Elsevier Ltd. All rights reserved.

Shares of BioNTech SE were soaring in early Monday trading, after Bristol Myers Squibb Co. made an $11.1 billion splash in the rapidly growing new cancer-drug game. The deal announced by Bristol ...

Alfred L. Garfall, MD, provided a deep dive into the phase 2 BMT CTN 1902 trial of ide-cel in multiple myeloma after transplant. Idecabtagene vicleucel (ide-cel; Abecma) showed impressive efficacy and ...

Johnson & Johnson currently boasts one of the largest lineups of multiple myeloma products. Since its first FDA approval of a drug for this type of blood cancer a decade ago, the pharmaceutical ...

Among patients who received four-drug consolidation therapy ... "Another question is how do we apply the MIDAS data to high-risk multiple myeloma?" Lentzsch continued. "Only a very small ...